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1302 | RSC Adv., 2014, 4, 1302–1309Dual functionality of conjugated polymer
nanoparticles as an anticancer drug carrier and a
ﬂuorescent probe for cell imaging†
O¨. Gezici,a I˙. Durmaz,b E. Bilget Gu¨ven,b O¨. U¨nal,a A. O¨zgu¨n,c R. Cetin-Atalayb
and D. Tuncel*ac
Multifunctional nanoparticles based on a green emitting, hydrophobic conjugated polymer, poly[(9,9-bis
{propeny}ﬂuorenyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT), that acts both as a ﬂuorescent
reporter and a matrix to accommodate an anti-cancer compound, camptothecin (CPT), were prepared,
characterized and their potential as a ﬂuorescent probe for cell imaging and as a drug delivery vehicle
were evaluated via in vitro cell assays. The cell viability of human hepatocellular carcinoma cell line
(Huh7) was investigated in the absence and presence of CPT with sulforhodamine B (SRB) and real-time
cell electronic sensing (RT-CES) cytotoxicity assays.Introduction
Nanoparticulate anti-cancer drug carrying systems oﬀer many
advantages over conventional chemotherapy.1,2 In the latter
treatment, the drugs may not approach the target easily or be
expelled from the body in a very short time and, as a result, the
treatment may require the usage of higher doses of the drugs; in
turn, this may cause unwanted side eﬀects. On the other hand,
the former has the potential to enable the preferential delivery
of drugs to tumors due to the enhanced permeability and
retention (EPR) eﬀect, in which the vasculature in tumors is
leaky to certain sizes of molecules (e.g. liposomes, nanoparticles
and macromolecular drugs) which allows these molecules to
accumulate in tumor tissues more than in normal tissues.3,4
Various nanostructured-materials in diﬀerent geometries have
been designed and synthesized from inorganic nanoparticles,
polymers, lipids and dendrimers to be used as contrast agents,
therapeutics, and delivery vehicles.5–11 For biomedical applica-
tions, nanoparticles smaller than 100 nm in diameter have been
suggested to be ideal because of their favorable bio-distributionersity, 06800 Ankara, Turkey. E-mail:
etics, Bilkent University, 06800 Ankara,
ology, Bilkent University, 06800 Ankara,
(ESI) available: 1NMR, 13C-NMR and
ropenyl)-9H-uorene, DLS histograms
lymer solutions, UV-vis spectra of CPT,
rescence spectra of CPT, CPNs and
of the dialysates obtained from the
ra45120hand excretion/accumulation behavior compared to their smaller
counterparts.7–9
Lately, a new class of water-dispersible nanoparticles based
on conjugated polymers (CPNs) have attracted signicant
attention.12–14 They exhibit low cytotoxicity, signicant photo-
stability, and possess high uorescent quantum yields and
molar absorptivity. Moreover, they can be easily synthesized
with desired emission wavelengths and functionalities from a
number of diﬀerent polymers.15–19 These features make them
very attractive for photonics20–22 and biomedical applica-
tions.23–32 Cellular uptake and cytotoxicity studies of CPNs based
on various conjugated polymers have been reported, and these
studies have clearly demonstrated that CPNs were taken up
eﬃciently by the cells through endocytosis even in a very short
incubation time.33 Nanoparticles have also been prepared for
drug delivery through the electrostatic assembly of a cationic
polyuorene based conjugated polymer with doxorubicin
conjugated anionic poly(L-glutamic acid).34 However, to the best
of our knowledge, there are no reports on the facile synthesis of
drug-loaded conjugated polymer nanoparticles through a
reprecipitation method using only one type of polymer, and
their dual use for drug delivery and imaging.
Here, we report on multifunctional CPNs which can be used
for drug delivery and cell imaging. First, nanoparticles with an
average diameter of about 25 nm and based on a green emitting,
hydrophobic conjugated polymer, poly[(9,9-bis{propeny}uo-
renyl-2,7-diyl)-co-(1,4-benzo-{2,1,3}-thiodiazole)] (PPFBT) were
prepared, characterized and their suitability as a uorescent
marker for cell imaging was evaluated by in vitro cell assays.
Then, drug loaded nanoparticles in which PPFBT acts both as a
uorescent reporter and a matrix to encapsulate an anticancer
drug, camptothecin (CPT), were synthesized through a facile,
single step reprecipitation method. CPT is a quinolineThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinealkaloid-based chemotherapy drug which accomplishes its
anticancer activity by inhibiting the DNA topoisomerase-I
activity.35,36 However, one of the drawbacks which prevents its
wide clinical use is its poor water solubility. Although water-
soluble analogues have been synthesized and tested for their
anticancer activity, they exhibited adverse side eﬀects due to the
solubilizing groups attached to the CPT backbone. Therefore, to
address this solubility problem, it is highly desirable, and one of
the objectives of this work, to achieve this through
encapsulation.Experimental section
All reagents were purchased from Sigma-Aldrich Chemical Co.
and were used as received. Morphological characterization was
achieved by atomic force microscopy-PSIA (AFM, XE-100E) and
transmission electron microscopy (TEM, FEI Tecnai G2 F30).
Negative staining with phosphotungstic acid was applied in
order to obtain TEM images. The size of the nanoparticles was
measured by dynamic light scattering (DLS, Zetasizer Nano-ZS).
Measurements were carried out at 633 nm and the laser, as the
light source, was used at room temperature. The time-depen-
dent autocorrelation function of the scattered light intensity
was measured at an angle of 90. The average particle diameter
was calculated by the Marquardt method. The DLS measure-
ments were usually repeated at least three times and the average
values are reported. For the optical characterization, a UV-vis
spectrophotometer (Cary UV-vis) and a uorescence spectro-
photometer (Cary Eclipse Fluorescent spectrophotometer)
equipped with a xenon-lamp as the excitation source were used.
For the structural characterization, nuclear magnetic resonance
(NMR, a Bruker Avance III 400 for 1H and a 100 MHz spec-
trometer for 13C) and FT-IR (Bruker TENSOR 27) spectra were
obtained. Each sample was dropped onto a silicon wafer. The
data were recorded at 25 C, in the spectral range of 4000–400
cm1, by accumulation of 256 scans with a resolution of 4 cm1.
Autoclaved ddH2O was used to prepare the nanoparticles. The
molecular weight of the polymers was determined using gel
permeation chromatography (GPC, Agilent 1200) with THF as
the eluent and polystyrene as the standard.Synthesis of 2,7-dibromo-9,9-bis-(propenyl)-9H-uorene
2,7-Dibromouorene (3.0 g, 9.25 mmol) and tetrabutylammo-
niumbromide (TBAB) (0.6 g, 1.85 mmol) were dried under
vacuum for 30 min. Degassed DMSO (15 mL), 50% (w/w) NaOH
(15 mL), allylbromide (16 mL, 90 mmol) were added into the
mixture respectively and stirred under argon gas for two hours
at room temperature. Aer two hours, t-butyl methyl ether
(125 mL) and deionized water (50 mL) were added to the
mixture and stirred 15min. The organic layer was separated and
subsequently washed with deionized water (50 mL), 2 N HCl
(50 mL), a brine solution (50 mL) and deionized water (50 mL),
respectively. Aer extraction, t-butyl methyl ether was evapo-
rated in a rotary evaporator and themonomer was obtained. For
the purication of the product, silica-packed column chroma-
tography was used and cyclohexane was used as the eluent.This journal is © The Royal Society of Chemistry 2014The solid was further puried by dissolving it in CHCl3 and
recrystallizing it with cold methanol. Colorless crystals were
collected and dried under vacuum (3.3 g, 89%).
1H-NMR (400 MHz, CDCl3): d 7.52 (m, 6H, Ar–H), 5.21
(m, 2H, –CH]CH2), 4.89 (m, 4H, –CH]CH2), 2.68 (t, 4H, –CH2–,
3J¼ 4 Hz). 13C-NMR (100 MHz, CDCl3): d 43.2, 54.7, 118.5, 121.2,
127.0, 130.5, 132.6, 138.7, 151.1. Elemental analysis: calc.: C,
56.47; H, 3.99; found: C, 56.12; H, 4.08%. ESI-MS:m/z 401.8 [M]+.
Synthesis of poly[(9,9-bis{propeny}uorenyl-2,7-diyl)-co-(1,4-
benzo-{2,1,3}-thiodiazole)] (PPFBT)
2,1,3-Benzothiadiazole-4,7-bis (boronic acid pinocol ester)
(573 mg, 1.47 mmol), 2,7-dibromo-9,9-bis-(propenyl)-9H-uo-
rene (500 mg, 1.47 mmol) and K2CO3 (2.04 g, 14.7 mmol) were
dried under vacuum about 30 min. First, degassed solvents,
THF (10 mL), water (10 mL) and toluene (10 mL), were added
under argon gas and then the catalyst tetrakis (triphenylphos-
phine) palladium (Pd(PPh3)4) (20 mg, 0.018 mmol) was added
quickly. Aer stirring the mixture for 3 h under argon at 80–
90 C, the phase transfer catalyst, tetra-n-butylammonium
bromide (TBAB) (30 mg) was added. The stirring was continued
for another 48 h at 80–90 C to complete the polymerization
reaction. The mixture was evaporated under vacuum to obtain a
solid residue that was then suspended in water. The water
insoluble particles were collected by ltration and dissolved in
THF (20 mL), followed by the addition of cold methanol
(200 mL). The precipitate was collected by ltration and dried
under vacuum for 5 h (646 mg, 60%).
1H NMR (400 MHz, CDCl3, d): 8.15 (m, 8H, Ar–H), 5.60 (m,
2H, –CH]CH2), 5.0 (t, 4H, –CH]CH2), 2.91 (t, 4H, –CH]CH2).
IR (KBr, pellet, ymax(cm
1)): 3074 (–CH, w), 2918 (–CH, s), 1455
(C]C–, w). GPC: Mn ¼ 4.5  103 g mol1, Mw ¼ 1.1  104 g
mol1, PDI ¼ 2.4 (polystyrene as standard).
Preparation of the nanoparticles
PPFBT (2.0 mg, 5.26  103 mmol, based on per repeating unit)
was dissolved in THF (5 mL). The resulting solution was soni-
cated for 30 min and then injected rapidly into autoclaved
double distilled water (50 mL). It was stirred under sonication
for further 30 min. THF was removed under reduced pressure.
The resulting nanoparticle solution was concentrated by evap-
orating its water under reduced pressure to get a concentration
of PPFBT of 0.75 mg mL1 (1.98  103 mmol mL1).
Preparation of drug loaded nanoparticles: determination of
drug loading capacity and entrapment eﬃciency
Five sets of drug-loaded nanoparticles were prepared with drug
to polymer ratios of 1 : 0.5 (w/w), 1 : 1 (w/w), 1 : 2 (w/w), 1 : 10
(w/w) and 1 : 25 (w/w).
The following is the typical procedure for the preparation of
the drug loaded nanoparticles (drug to polymer ratio: 1 : 25 (w/
w)): PPFBT (2.0 mg, 5.26  103 mmol, based on per repeating
unit) and CPT (0.08 mg, 0.23  103 mmol) were dissolved in
THF (5 mL). The resulting solution was sonicated for 30 min
and then injected rapidly into autoclaved double distilled water
(50 mL). It was stirred under sonication for further 30 min. THFRSC Adv., 2014, 4, 1302–1309 | 1303
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View Article Onlinewas removed under reduced pressure and the CPN dispersion
was concentrated to 5 mL and dialyzed against water using a
14 kDa MWCO regenerated cellulose membrane for 24 h to
remove any remaining free CPT. Tween 20 (0.2%, v/v) was added
to the dialysate to solubilize the free CPT. UV-vis absorbance
spectra (lmax ¼ 366 nm) of the dialysates were recorded to
determine the concentration of CPT. Samples of known
concentration of CPT dissolved in water containing Tween 20
(0.2%, v/v) were used to obtain a calibration curve of CPT.
In vitro drug-release studies
10mM phosphate buﬀer saline (PBS) containing 0.2% Tween 20
was used as the release medium to improve the drug solubility.
A 3 mL aliquot of the drug encapsulated nanoparticle disper-
sion was mixed with 7 mL of PBS and transferred into a cellu-
lose tubular membrane with a molecular weight cut-oﬀ of
14 kDa. A dialysis tube was placed in a beaker containing
100mL of PBS and 0.2 wt% Tween 20 and shaken at 60 RPM and
37 C in an incubator. A 1 mL aliquot was withdrawn from the
dialysate at diﬀerent time intervals during the 110 hours and, at
each time, equal amounts of fresh PBS was added to the dialy-
sate beaker to prevent sink conditions. The concentration of
CPT in the release medium was measured by using absorption
spectrophotometry (lmax ¼ 366 nm).
Preparation of cells and culture medium
Human hepatocellular carcinoma cell line Huh7 was main-
tained in a Dulbecco’s Modied Eagle’s Medium (DMEM)
(Invitrogen GIBCO) with 10% fetal bovine serum (FBS) (Invi-
trogen GIBCO), non-essential amino acids and 1% penicillin
(Biochrome). Huh7 cells were incubated at 37 C with 5% CO2.
DMSO (Sigma) was used as the solvent for camptothecin (Cal-
biochem) at a concentration less than 1% in the cell culture
medium.
Cytotoxicity assays
Initial screening of the compounds for cytotoxic activity was
conducted by using the NCI-60 Sulforhodamine B (SRB)
Colorimetric assay.37–39 In order to assess the real-time cell
analysis (RT-CES, ACEA Biosciences), rst a steady imped-
ance value was obtained by adding 50 mL of cell culture media
to each well of the 96 e-plate (Roche Applied Sciences).
Then, human liver cancer cells (Huh7) were inoculated (2000
cell per well). The attachment, spreading, and proliferationScheme 1 Synthesis of poly[(9,9-bis{propeny}ﬂuorenyl-2,7-diyl)-co-(1,4
DMSO, TBAB, 2 h, RT, 89%, (b) Pd(PPh3)4, K2CO3, THF–H2O, 80 C, 48 h
1304 | RSC Adv., 2014, 4, 1302–1309of the cells were monitored every 30 minutes using RT-CA in a
cell culture incubator. 24 hours later, as the cells reached
their log growth phase, they were treated with various
concentrations of the compounds (from 1 mM to 0.06 mM).
For the control, only DMSO or only ddH2O was added to the
wells. The experiments were conducted in triplicate. The
electronic readout (cell-sensor impedance) was displayed at
an arbitrary unit called the cell index (CI). The CI value
was noted every 10 minutes for the rst 24 hours and
then every 30 minutes. The cell inhibition rate (%) ¼
(1  CItreated cells/CIDMSO)  100.
Cell staining and imaging
Huh7 cells plated on coverslips and treated with CPT,
CPT-loaded CPNs, DMSO only and CPNs only for 24 h and 72 h
were MeOH (100%, ice-cold) xed prior to staining. Then, two
drops per mL of medium of ActinRed 555 Ready Probes Reagent
(Invitrogen) was added. Following a 30 min dark incubation,
cells were washed with PBS and then counter-stained with 1 mg
mL1 Hoechst 33258. Coverslips de-stained with ddH2O were
mounted on glass slides and examined under a uorescence
microscope (Nikon ECLIPSE 50i).
Results and discussion
The polymer PPFBT, which contains a propenyl group as a side
chain, was synthesized using the Suzuki coupling reaction of
2,7-dibromo-9,9-bis-(propenyl)-9H-uorene and 1,2,3-benzo-
thiadiazole-4,7-bis(boronic acid pinocol ester) as shown in
Scheme 1. The 9,9-position of the uorene was substituted with
the propenyl group because, if necessary, the nanoparticles
made from PPFBT could be stabilized through light-induced
cross-linking of the double bonds to form a cross-linked shell or
targeting groups/biomolecules could be attached to the nano-
particles through thiol-en click chemistry for further
applications.
The polymer PPFBT was puried by precipitation of the
polymer solution in THF with cold methanol to provide an
orange powder in 60% yield which was characterized by
1H-NMR spectroscopy, UV-vis spectroscopy, uorescence spec-
troscopy and FT-IR spectroscopy. The 1H-NMR spectrum of
PPFBT is shown in Fig. 1 which conrms the desired structure
of the polymer.
Conjugated polymer nanoparticles (CPNs) were prepared by a
simple reprecipitationmethod in which a PPFBT solution in THF-benzo-{2,1,3}-thiodiazole)] PPFBT. (a) Allylbromide, 50% NaOH (aq.),
, 60%.
This journal is © The Royal Society of Chemistry 2014
Fig. 1 1H-NMR (400 MHz, CDCl3, 25 C) spectrum of PPFBT.
Fig. 3 Entrapment and loading eﬃciencies of the nanoparticles with
various drug to polymer ratios.
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View Article Onlinewas injected into a large excess of water under sonication. Aer
removal of the THF under reduced pressure, stable CPNs were
obtained. We should also mention that the concentration of the
polymer solution used in the nanoparticle synthesis directly
aﬀects the size of the nanoparticles as it has also been reported in
the literature previously.16–18 We have prepared nanoparticles
with average diameters of 25 nm, 76 nm, 103 nm and 155 nm by
varying the concentration of the polymer solution (see ESI,
Fig. S4,† for their DLS histograms). In this study, we opted to use
the nanoparticles with the average diameter of 25 nm.
The optical properties of the nanoparticles were investigated
by UV-vis and uorescence spectroscopy and compared to the
polymer in THF and in solid state (Fig. 2).
Maximum absorption peaks were observed at 317 and 447
nm for the polymer in THF; these are almost the same for the
CPNs in water and approximately 10 and 25 nm red shied for
the lm of polymer. However, when CPNs were excited at 447
nm, a green-yellow emission band at 550 nm was observed,
which was 13 nm red shied compared to the emission band of
the polymer in THF. If the emission wavelength of CPNs is
compared to the emission wavelength of the polymer lm, it can
be seen that there is only 8 nm of diﬀerence between them (550
nm for the CPNs water dispersion and 558 nm for the polymer
lm) indicating that the optical properties of the nanoparticles
resembles those of the polymer’s solid state. The quantumFig. 2 UV-vis absorption and emission spectra of PPFBT in THF (lexc.¼
447 nm) and as a ﬁlm (lexc. ¼ 472 nm), and of a dispersion of the
nanoparticles in water (lexc. ¼ 447 nm).
This journal is © The Royal Society of Chemistry 2014yields of PPFBT in THF and the dispersion of CPNs in water
were calculated as 70% and 26%, respectively, using uorescein
dye as the standard. The red shi of the emission maximum for
the CPNs compared to the polymer in THF indicates the
aggregation of polymer chains upon the nanoparticle formation
in water. As a result of this aggregation, the overlap of p-orbitals
increases, followed by p-electron delocalization across the
chains. The lower band gaps, indicated by the red shi, are a
sign of this delocalization. Similarly, the red shi in the
emission maximum of the polymer in solid state is the result of
the tight packing of the polymer chains.17–19,29Fig. 4 Schematic representation of the p–p interactions between the
aromatic polymer backbone and the aromatic rings of CPT.
RSC Adv., 2014, 4, 1302–1309 | 1305
Fig. 5 TEM images of CPNs (a) and CPT-loaded CPNs (b); the insets are their AFM images (scale: 0.5  0.5 mm). Dynamic light scattering
histograms of CPNs (c) and CPT-loaded CPNs (d).
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View Article OnlineCamptothecin loaded CPNs were prepared in a single step
synthesis as described in the experimental section. In order to
determine the loading and entrapment eﬃciency of the nano-
particles, ratios of CPT to PPFBT (w/w) 1 : 0.5, 1 : 1, 1 : 2, 1 : 10
and 1 : 25 were used during the nanoparticle preparation. In
each case, aer the nanoparticle formation, the dispersion was
dialyzed against water using a 14 kDa MWCO regenerated
cellulose membrane for 24 h to remove any remaining unen-
capsulated CPT. The dialysates were analyzed by recording their
absorption spectra (lmax ¼ 366 nm) (ESI, Fig. S6†) and the
unencapsulated CPT concentration was calculated from a
calibration curve of CPT which was constructed from known
concentrations of CPT solutions (ESI, Fig. S5†). The entrapment
eﬃciency (EE) and loading eﬃciency (LE) were calculated
according to the following equations and the results are plotted
in Fig. 3.
EE % ¼ loaded drug wt/total drug wt  100
LE % ¼ loaded drug wt/total system wt  100
In Fig. S7 (ESI†), the UV-vis absorption and the emission
spectra of CPT-loaded CPNs, a CPN dispersion in water and CPT
in water containing Tween 20 (0.2%, v/v) are compared. The
main driving forces for the encapsulation of CPT by PPFBT to
form drug-loaded nanoparticles are probably the hydrophobicFig. 6 The time-dependent release proﬁle of CPT from the
nanoparticles.
1306 | RSC Adv., 2014, 4, 1302–1309eﬀect and the p–p interactions between the aromatic polymer
backbone and the aromatic rings of CPT as shown schemati-
cally in Fig. 4.Fig. 7 Real-time growth inhibitory eﬀect of loaded and blank CPNs
with camptothecin on the human liver (Huh7) cancer cell line for 24 h,
48 h and 72 h incubation periods. The cytotoxicity eﬀects were
determined by RT-CES. The experiments were conducted in triplicate.
This journal is © The Royal Society of Chemistry 2014
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View Article OnlineThe synthesis of blank CPNs and CPT-loaded CPNs was
repeated more than three times by keeping the synthetic
conditions constant. Their size was determined by dynamic
light scattering (DLS) measurements (Fig. 5c and d) and the
average of three diﬀerent DLS measurements was calculated to
be 25.50  0.76 nm for the CPNs and 24.38  1.37 nm for the
drug loaded CPNs. The morphology of the CPNs and CPT-
loaded CPNs was studied by TEM (Fig. 5) and AFM imaging
techniques. The zeta potential values were measured as 51.17
 2.16 and 29.80  6.52 eV for CPNs and 40.70  4.82 eV for
CPT-loaded CPNs, which indicate the formation of stable
nanoparticle dispersions caused by repulsion between the
nanoparticles. As it can be seen from the DLS measurements
and TEM images, no signicant changes are observed in their
diameter, indicating that the structural integrity of the nano-
particles is not aﬀected when they are loaded with drug. The
reason could also be attributed to the p–p interactions betweenFig. 8 Fluorescence images of Huh7 cells plated on coverslips and treat
as the control at concentrations of 0.125 mM after (A) 24 h and (B) 72 h inc
33258 (c and d) and the red ﬂuorescence from ActinRed 555 Probes (In
This journal is © The Royal Society of Chemistry 2014the aromatic conjugated backbone of the polymer chains and
the aromatic rings of the CPT molecules, causing a close
packing of the drug molecules. Recently, similar results have
also been observed by Hennink and co-workers.40
The in vitro drug release prole of the CPT-loaded nano-
particles was investigated in PBS (pH 7.4, 37 C) as described in
the experimental section, and the release prole of CPT from
the nanoparticles is shown in Fig. 6. The time-dependent
release prole of CPT from the nanoparticles was measured by
the absorption at 366 nm with UV-vis spectrophotometry. Over
the rst 18 h, about 50% of the loaded CPT was released,
followed by a sustained release for up to 5 days.
Time and dose dependent in vitro cytotoxicity tests of blank
CPNs, CPT-loaded CPNs and free CPT against Huh7 cells were
performed by RT-CES and the results are plotted in Fig. 7. In this
experimental set-up, free CPT was used as a positive control and
DMSO and blank CPNs were used as negative controls to theed with green emitting CPT-loaded CPNs, unloaded-CPNs and ddH2O
ubations. The blue ﬂuorescence arises from the nuclear stain Hoechst
vitrogen). Images were acquired with a 20 objective.
RSC Adv., 2014, 4, 1302–1309 | 1307
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View Article OnlineCPT-loaded CPNs. The cytotoxicity assay of the blank CPNs
indicates that they are not toxic to the Huh7 cells up to a
concentration of 25 mM. CPT caused almost 100% growth inhi-
bition at all doses except at 0.06 mM (Fig. S9, ESI†). This
behaviour indicates the activation of the necrosis pathway,
which is not the preferred death pathway in cancer treatment
but apoptosis. Moreover, the small increase in the growth inhi-
bition of the blank CPNs (CPN unloaded) aer 12 hours is
probably not due to cell death. RT-CES experiments involve
using a gold plate and the system relies on electrical impedance
cell sensors arrays embedded at the bottom of the plates. Even
though there is no cell death, any change in the size of the cells
can also be interpreted as growth inhibition. Therefore, the
quick increase in the unloaded CPN samples was probably not
due to cell death but to a change in the size of the cells caused by
the addition of the unloaded CPN solution to the culture media.
CPT-loaded CPNs were analyzed by uorescence micros-
copy on Huh7 cells. In Fig. 8 (see also Fig. S8, ESI†), the bright
green CPN emission is evidence of an eﬃcient cellular inter-
nalization. Especially, at 24 h, the nuclei seem to be densely
populated with CPT-loaded CPNs (Fig. 8A). Aer 72 h, the
CPNs leave the cellular nuclei and exit the cellular nuclei in
vesicle form (Fig. 8B). No green emission was observed in the
ddH2O controls as expected due to the lack of CPNs. The red
uorescence indicates the presence of actin cytoskeletons and
the blue uorescence emitted by the Hoechst stain indicates
the nuclei.
The high eﬃcacy of this approach can be attributed to a
number of factors. Amongst them, the drug-loaded nano-
particles have the potential to avoid multidrug resistance
mechanisms (MRMs) when they enter the cells via endocy-
tosis.41 MRMs operate through transmembrane drug eﬄux
pumps involving cell-surface proteins such as glycoproteins
which can prevent small drugs to enter the cells. CPT is a water
insoluble drug molecule which dissolves in organic solvents
(e.g. DMSO) or in acidied water. None of them are desirable as
DMSO has toxic eﬀects to the cells and CPT molecules are
hydrolyzed in acidic aqueous media which, in turn, causes their
inhibitory activity to decrease. However, encapsulation provides
the CPTmolecules with both water solubility and the stability to
preserve their full activity.
Conclusions
In conclusion, we have presented a new and simple approach
for the development of multifunctional nanoparticles, which
can perform simultaneously drug delivery and cell imaging
tasks. In this approach, the water-insoluble drug campto-
thecin was incorporated into the conjugated polymer nano-
particles with a very high loading eﬃciency due to favourable
non-covalent interactions (e.g. hydrophobic eﬀect and p–p
interactions) between the aromatic backbone of the polymer
chains and the drug molecules. The drug-loaded nano-
particles were uniform in size, size distribution and surface
charge. The time and dose dependent cytotoxicity assay
results indicated that these nanoparticles achieve the
delivery of water-insoluble anticancer drugs into cancer cells1308 | RSC Adv., 2014, 4, 1302–1309(Huh7) in an eﬃcient manner leading to eﬀective growth
inhibition and therefore cell death. Furthermore, the long
term controlled release of CPT from the CPNs is preferable in
clinical research for the increased eﬀectiveness of its cyto-
toxicity. Noticeably, this new imaging-guided drug delivery
system does not require a complicated design and synthetic
methodology, as it requires only one type of polymer, which
can be synthesized easily, that acts both as a photostable
uorescent probe and a matrix to encapsulate the drug
molecules.
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